Your session is about to expire
← Back to Search
Behavioural Intervention
Virtual Reality Self-Hypnosis for Pain Relief
N/A
Waitlist Available
Research Sponsored by Icahn School of Medicine at Mount Sinai
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Average pain intensity of 3 or greater on the NRS of the mean daily scores reported between Visit 1 and Visit 2
Documentation of chronic pain associated with HIV for ≥90 days
Must not have
Injury to eyes, face, or neck that impedes using the VR device
Current or prior diagnosis of epilepsy, seizure disorder, dementia, migraines, or other neurological conditions contraindicating the use of virtual reality devices
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at week 2, 3 and week 4
Awards & highlights
No Placebo-Only Group
Summary
This trial is looking at whether a self-hypnosis software, used with a virtual reality device, can help to relieve pain in HIV patients. The study will assess the safety, usability, and effectiveness
Who is the study for?
This trial is for individuals with chronic pain related to HIV, including musculoskeletal and neuropathic pain. Participants should be comfortable using a VR headset as part of the treatment process.
What is being tested?
The study tests a self-hypnosis software delivered through an OculusGo™ VR device, aiming to assess its safety, ease of use, and initial effectiveness in managing HIV-associated chronic pain.
What are the potential side effects?
Since this involves non-invasive VR technology, side effects may include dizziness or nausea due to virtual reality immersion but are generally expected to be minimal.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My average pain level is 3 or higher on a scale of 0-10.
Select...
I have had chronic pain related to HIV for at least 90 days.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have an injury to my eyes, face, or neck that prevents me from using VR devices.
Select...
I have never been diagnosed with epilepsy, migraines, or other conditions that prevent me from using VR devices.
Select...
I either can't see in 3D or have severe hearing loss.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at week 2, 3 and week 4
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at week 2, 3 and week 4
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of adverse events related to the device
Number of times the software is used
Secondary study objectives
Quality of Life measured using Pain, Enjoyment and General Activity Scale (PEG)
Quality of life measured using Short Form Brief Pain Inventory (SF-BPI) Scale
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: HIV-associated Chronic Pain PatientsExperimental Treatment1 Intervention
The participants will be enrolled into an open label arm to determine feasibility and useability of the combination device.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Virtual Reality headset
2017
N/A
~50
Find a Location
Who is running the clinical trial?
Icahn School of Medicine at Mount SinaiLead Sponsor
909 Previous Clinical Trials
542,135 Total Patients Enrolled
6 Trials studying Neuralgia
276 Patients Enrolled for Neuralgia